Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2013.08.053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A prospective study on the early evaluation of response to androgen receptor-targeted agents with C-Choline, Ga-PSMA, and F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience.
ESMO Open
May 2024
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna.
Article Synopsis
- The study focuses on identifying effective treatment responses in patients with metastatic castration-resistant prostate cancer (mCRPC) using positron emission tomography (PET) with different radiotracers.
- A total of 49 patients were randomly assigned to receive scans using C-Choline, F-FACBC, or Ga-PSMA before treatment and again 2 months later to evaluate their biochemical response, primarily looking for a PSA reduction of ≥50%.
- Results indicated that variations in metabolic tumor volume (MTV) and total lesion activity (TLA) with Ga-PSMA PET were significantly associated with treatment responses and could also predict progression-free survival and overall survival in patients.
Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [F]F-FDG Tracers Part II. [F]F-FLT, [F]F-FET, [C]C-MET and Other Less-Commonly Used Radiotracers.
Semin Nucl Med
March 2024
Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria. Electronic address:
Following the previous part of the narrative review on artificial intelligence (AI) applications in positron emission tomography (PET) using tracers rather than F-fluorodeoxyglucose ([F]F-FDG), in this part we review the impact of PET-derived radiomics data on the diagnostic performance of other PET radiotracers, F-O-(2-fluoroethyl)-L-tyrosine ([F]F-FET), F-Fluorothymidine ([F]F-FLT) and C-Methionine ([C]C-MET). [F]F-FET-PET, using an artificial amino acid taken up into upregulated tumoral cells, showed potential in lesion detection and tumor characterization, especially with its ability to reflect glioma heterogeneity. [F]F-FET-PET-derived textural features appeared to have the potential to reveal considerable information for accurate delineation for guiding biopsy and treatment, differentiate between low-grade and high-grade glioma and related wild-type genotypes, and distinguish pseudoprogression from true progression.
View Article and Find Full Text PDFDiagnostic Accuracy of PET with F-Fluciclovine ([F]FACBC) in Detecting High-Grade Gliomas: A Systematic Review and Meta-Analysis.
Diagnostics (Basel)
December 2023
Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Background: F-Fluciclovine ([F]FACBC) has been recently proposed as a synthetic radiolabeled amino acid for positron emission tomography (PET) imaging in patients with brain neoplasms. Our aim is to evaluate the diagnostic performance of [F]FACBC PET in high-grade glioma (HGG) patients, taking into account the literature data.
Methods: A comprehensive literature search was performed.
The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years.
Curr Med Imaging
May 2023
Department of Medical Science, Division of Nuclear Medicine, University of Turin, Turin, Italy.
Background: Breast cancer is the most common malignancy in women, with high morbidity and mortality. Molecular alterations in breast cancer involve the expression or upregulation of various molecular targets that can be used for diagnostic nuclear medicine imaging and radiopharmaceutical treatment. Theragnostics is based on the binding of radionuclides to molecular targets.
View Article and Find Full Text PDFComparison of [F]fluciclovine and [F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients.
Mol Imaging Biol
October 2022
Division for Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Purpose: [F]FDG PET/CT in multiple myeloma (MM) is currently the best technology to demonstrate patchy and extramedullary disease. However, [F]FDG PET has some limitations, and imaging with alternative tracers should be explored. In this study, we aimed to evaluate the performance of [F]fluciclovine PET compared to [F]FDG PET in newly diagnosed MM patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!